Literature DB >> 22379619

Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis? 1975.

Howard Schatz, Lawrence A Yannuzzi, Kurt A Gitter.   

Abstract

The diagnosis of central serous chorioretinopathy is usually confirmed by the fluorescein angiographic finding of one or more pinpoint pigment epithelial leaks in or near a macula with a detached sensory retina. When argon laser photocoagulation is used to treat pigment epithelial leaks, resolution of the leaks occurs with reattachment of the sensory retina. We have seen six patients for whom a diagnosis of central serous chorioretinopathy was made; argon laser photocoagulation was carried out and subsequently followed by postoperative subretinal neovascularization often accompanied by hemorrhage, exudate and, in some cases, progressive reduction in visual acuity. Since the presentation of this paper to the American Academy of Ophthalmology and Otolaryngology in 1975, we have received photographs and case reports of 21 additional patients. This paper discusses these 27 cases and demonstrates the causes of the postoperative development of subretinal neovascularization

Entities:  

Mesh:

Year:  2012        PMID: 22379619     DOI: 10.1097/iae.0b013e318242fa2d

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.

Authors:  Lijun Zhou; Victor Chong; Kunbei Lai; Chuangxin Huang; Fabao Xu; Yajun Gong; Maimaitiaili Youlidaxi; Tao Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

2.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

3.  Peripapillary nerve fiber layer thickness changes after macular photocoagulation for clinically significant diabetic macular edema.

Authors:  Khalil Ghasemi Falavarjani; Ali Khoshamadi; Naveed Nilforushan
Journal:  Saudi J Ophthalmol       Date:  2014-10-08

Review 4.  A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders.

Authors:  Paula Scholz; Lebriz Altay; Sascha Fauser
Journal:  Adv Ther       Date:  2017-05-24       Impact factor: 3.845

5.  Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases.

Authors:  Wipada Laovirojjanakul; Thuss Sanguansak; Yosanan Yospaiboon; Supat Sinawat; Suthasinee Sinawat
Journal:  Case Rep Ophthalmol       Date:  2017-08-08

6.  Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy.

Authors:  Lisa Toto; Rossella D'Aloisio; Chiara De Nicola; Federica Evangelista; Maria Ludovica Ruggeri; Luca Cerino; Maria Beatrice Simonelli; Agbéanda Aharrh-Gnama; Marta Di Nicola; Annamaria Porreca; Rodolfo Mastropasqua
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

7.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25

8.  Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy.

Authors:  Zuhua Sun; Ying Huang; Chaochao Nie; Zhijie Wang; Junqing Pei; Bing Lin; Rong Zhou; Junyan Zhang; Victor Chong; Xiaoling Liu
Journal:  Eye (Lond)       Date:  2019-11-29       Impact factor: 3.775

9.  Subthreshold Micropulse Laser vs. Conventional Laser for Central Serous Chorioretinopathy: A Randomized Controlled Clinical Trial.

Authors:  Lijun Zhou; Kunbei Lai; Ling Jin; Chuangxin Huang; Fabao Xu; Yajun Gong; Longhui Li; Zhe Zhu; Lin Lu; Chenjin Jin
Journal:  Front Med (Lausanne)       Date:  2021-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.